-
公开(公告)号：US20120017011A1
公开(公告)日：2012-01-19
申请号：US12836341
申请日：2010-07-14
IPC分类号： G06F3/00
CPC分类号： G06F3/0604 , G06F3/0617 , G06F3/0659 , G06F3/067
摘要： A method, apparatus, system, and computer program product for enabling out-of-band access to storage devices through port-sharing hardware. Providing out-of-band access to storage devices enables system management functions to be performed when an operating system is non-functional as well as when the operating system is active. Storage commands originating with a management service can be interleaved with storage commands issued by the host operating system. The host operating system maintains ownership and control over its storage devices, but management activities can be performed while the host operating system is operational.
摘要翻译： 一种用于通过端口共享硬件对存储设备进行带外访问的方法，装置，系统和计算机程序产品。 提供对存储设备的带外访问可使系统管理功能在操作系统不起作用以及操作系统处于活动状态时执行。 源自管理服务的存储命令可以与主机操作系统发出的存储命令交错。 主机操作系统维护对其存储设备的所有权和控制权，但是可以在主机操作系统运行时执行管理活动。
-
公开(公告)号：USD631538S1
公开(公告)日：2011-01-25
申请号：US29334903
申请日：2009-04-03
-
公开(公告)号：US20090208581A1
公开(公告)日：2009-08-20
申请号：US12351328
申请日：2009-01-09
申请人： David A. Edwards , Howard A. Stone
发明人： David A. Edwards , Howard A. Stone
IPC分类号： A61K9/14 , C08B37/00 , C07K14/00 , A61K31/74 , A61K38/16 , A61K31/715 , C08B37/02 , C08G65/34 , C07K14/76 , A61K31/721 , A61K31/765 , A61K38/38 , A61P31/12 , A01K29/00 , A61D7/00
CPC分类号： A61K9/0075 , A61K9/0078 , A61K31/355 , A61K31/685 , A61K31/715
摘要： Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
摘要翻译： 已经开发了用于肺部输送以治疗或减少诸如人体中的重要感染，特别是结核病，SARS，流感和呼吸道合成病毒以及动物蹄和口蹄疫的疾病的感染性的制剂。 用于肺部给药的制剂包括显着改变诸如表面活性剂和任选的载体的肺粘液衬里液体的表面张力和表面弹性的物理性质的材料。 制剂可以粉末施用，其中颗粒基本上由改变表面张力的材料组成。 载体可以是溶液，例如醇，尽管可以使用水溶液，或与材料混合的材料改变表面张力以形成颗粒。 这些可以包括诸如白蛋白或多糖的蛋白质，例如还具有表面活性的葡聚糖，或聚合物如聚环氧乙烷（PEO）或可生物降解的合成聚合物，其可用于封装或递送待递送材料。 药物，特别是抗病毒剂或抗生素，可以任选地包括在制剂中。 这些可以与制剂一起施用或掺入制剂中。
-
公开(公告)号：US20090068274A1
公开(公告)日：2009-03-12
申请号：US12253449
申请日：2008-10-17
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1617 , A61K31/198
摘要： A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles.Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.
摘要翻译： 用于在单个呼吸激活步骤或单次呼吸中将药物递送至肺部系统的方法包括从包围大量颗粒的容器向受试者的呼吸道施用具有小于 0.4克/厘米3，并输送至少约50％的颗粒。 颗粒能够携带。 试剂是（1）部分喷雾干燥预混合物，由此加入到颗粒中，（2）加入到单独制备的颗粒中，使得试剂与颗粒化学缔合，或（3）混合 试剂与颗粒混合并与颗粒共同传送。 还公开了包含振实密度小于0.4g / cm 3的载体颗粒和包含试剂的组合物的可吸入组合物。 还包括递送这些可呼吸组合物的方法。
-
公开(公告)号：US20080213373A1
公开(公告)日：2008-09-04
申请号：US11720595
申请日：2005-10-19
申请人： David A. Edwards , Jennifer Fiegel , Jean Sung
发明人： David A. Edwards , Jennifer Fiegel , Jean Sung
IPC分类号： A61K9/14
CPC分类号： A61K9/0075 , A61K9/1617 , A61K9/1694 , Y10S514/924
摘要： Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine.
摘要翻译： 已经开发了治疗或减少呼吸道感染传播的制剂，特别是慢性或耐药性感染，特别是结核病（TB），严重急性呼吸综合征（SARS），脑膜炎球菌性脑膜炎，呼吸道合胞病毒（RSV），流感和小痘 。 制剂包括纳米颗粒的微粒，纳米颗粒或骨料形式的药物或疫苗，以及任选的可以通过吸入递送的载体。 通过吸入器给药可以通过绕过胃和肝来避开与口服或可注射药物相关的问题，并将药物直接送入肺部。 在一个实施方案中，含有该试剂的颗粒是大的多孔气溶胶颗粒（LPPs）。 在另一个实施方案中，颗粒是纳米颗粒，其可以作为具有微米直径的多孔纳米颗粒聚集体施用，其在施用后分散到纳米颗粒中。 任选地，包覆纳米颗粒，例如用表面活性剂或蛋白质涂层。 制剂可以粉末形式施用或作为溶液给药或通过肠内或非肺部非肠道途径给药。 制剂优选作为肺制剂施用。 在用于治疗结核病的优选实施方案中，疫苗是在室温下稳定的BCG疫苗，或者是针对TB有效的抗生素，例如卷曲霉素或PA-824，其以非常高的百分比加载到微粒或纳米颗粒中。 在一个实施方案中，用递送抗生素和疫苗的制剂治疗患者。
-
公开(公告)号：US07048908B2
公开(公告)日：2006-05-23
申请号：US10202616
申请日：2002-07-23
CPC分类号： A61K9/0075 , A61K9/1617 , A61K38/28 , A61K47/544 , Y10S514/958
摘要： The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.
-
公开(公告)号：US06956021B1
公开(公告)日：2005-10-18
申请号：US09383054
申请日：1999-08-25
CPC分类号： A61K9/0075 , A61K9/1617 , Y10S514/951 , Y10S514/97 , Y10S514/975
摘要： Spray-dried particles having improved protein stability are produced by spray-drying a mixture including a protein, a phospholipid and an organic-aqueous co-solvent. Spray-dried particles which include at least 1 weight % phospholipid, having a tap density of less than 0.4 g/cm3 can be prepared. The particles can be delivered to the pulmonary system of a patient.
摘要翻译： 具有改善的蛋白质稳定性的喷雾干燥颗粒通过喷雾干燥包括蛋白质，磷脂和有机 - 水性共溶剂的混合物而产生。 包含至少1重量％磷脂的喷雾干燥颗粒，其振实密度小于0.4g / cm 3，可以制备。 颗粒可以输送到患者的肺部系统。
-
公开(公告)号：US06921528B2
公开(公告)日：2005-07-26
申请号：US10681416
申请日：2003-10-08
IPC分类号： A61K9/12 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/72 , A61K31/137 , A61K31/198 , A61K31/46 , A61K31/56 , A61K38/27 , A61K38/28 , A61K39/395 , A61L9/04 , B05D7/14
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1617 , A61K31/198
摘要： A method for delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single, breath-activated step, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. Another method of delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single breath, includes administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of at least 0.4 g/cm3 and deliver at least about 10 milligrams of the bioactive agent. The receptacle can have a volume of at least 0.37 cm3.
摘要翻译： 在单一呼吸激活步骤中将治疗剂量的生物活性剂递送到肺系统的方法包括从包围大量颗粒的容器向受试者的呼吸道施用具有较小振幅密度的颗粒 超过0.4g / cm 3，并输送至少约50％的质量的颗粒。 在单次呼吸中将治疗剂量的生物活性剂递送到肺系统的另一种方法包括从包围大量颗粒的容器向受试者的呼吸道施用具有至少0.4g / 并输送至少约10毫克的生物活性剂。 容器可具有至少0.37厘米3的体积。
-
公开(公告)号：US06858199B1
公开(公告)日：2005-02-22
申请号：US09591307
申请日：2000-06-09
IPC分类号： A61K9/12 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/72 , A61K31/137 , A61K31/198 , A61K31/46 , A61K31/56 , A61K38/27 , A61K38/28 , A61K39/395 , A61L9/04 , B05D7/14
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1617 , A61K31/198
摘要： A method for delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single, breath-activated step, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. Another method of delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single breath, includes administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of at least 0.4 g/cm3 and deliver at least about 10 milligrams of the bioactive agent. The receptacle can have a volume of at least 0.37 cm3.
摘要翻译： 在单一呼吸激活步骤中将治疗剂量的生物活性剂递送到肺系统的方法包括从包围大量颗粒的容器向受试者的呼吸道施用具有较小振幅密度的颗粒 超过0.4g / cm 3并且输送至少约50％的质量的颗粒。 在单次呼吸中将治疗剂量的生物活性剂递送到肺系统的另一种方法包括从包围大量颗粒的容器向受试者的呼吸道施用具有至少0.4g / 并输送至少约10毫克的生物活性剂。 容器可具有至少0.37厘米3的体积。
-
公开(公告)号：US06447752B2
公开(公告)日：2002-09-10
申请号：US09888781
申请日：2001-06-25
申请人： David A. Edwards , Giovanni Caponetti , Jeffrey S. Hrkach , Noah Lotan , Justin Hanes , Robert S. Langer , Abdellaziz Ben-Jebria
发明人： David A. Edwards , Giovanni Caponetti , Jeffrey S. Hrkach , Noah Lotan , Justin Hanes , Robert S. Langer , Abdellaziz Ben-Jebria
IPC分类号： A61K912
CPC分类号： A61K9/0075 , A61K9/1647 , A61K31/137 , Y10S514/826 , Y10S514/851
摘要： Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear &agr;-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 &mgr;m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The porous particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.
摘要翻译： 提供用于向肺系统递送药物的改进的多孔颗粒，以及用于其合成和给药的方法。 在优选的实施方案中，多孔颗粒由可生物降解的材料制成，其质量密度小于0.4g / cm 3 /。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如，颗粒可以由官能化聚酯接枝共聚物形成，该聚酯接枝共聚物由具有至少一个氨基酸基团的直链α-羟基酸聚酯主链和至少一个从氨基酸延伸的聚（氨基酸）侧链组成 集团在聚酯骨干。 在一个实施方案中，具有相对大的平均直径，例如大于5um的多孔颗粒可用于增强治疗剂递送至肺的肺泡区域。 掺入治疗剂的多孔颗粒可以有效地雾化，用于给予呼吸道以允许全身或局部递送多种治疗剂。
-
-
-
-
-
-
-
-
-
搜索结果
97 条记录 (耗时 0.054 秒)
